FINWIRES · TerminalLIVE
FINWIRES

SHA:600566

6 stories mentioning SHA:600566Updated 30d ago

Every FINWIRES story that references SHA:600566, newest first.

Asia

China Includes Hubei Jumpcan Pharmaceutical's Granules for Colds in Children in Essential Drug List

Chinese authorities included Hubei Jumpcan Pharmaceutical (SHA:600566) subsidiary Jumpcan Pharmaceutical's fermented soybean and forsythia clearing-heat granules for children in the country's essential medicines list, according to a Friday filing with the Shanghai bourse.The granules help treat childhood wind-heat colds with stagnation syndrome, the company said in its filing.Sales of the drug reached 264.1 million yuan in the first quarter.

SHA:600566
Asia

Jumpcan Pharma Gets Registration Certificate for Marboxil Tablets

Hubei Jumpcan Pharmaceutical (SHA:600566) obtained a drug registration certificate for marboxil tablets, according to a Shanghai bourse filing on Tuesday.The certificate was received through subsidiary Jichuan Pharmaceutical Group and Zenshine Pharmaceutical (Nanjing) Group.The drug is used for the treatment of uncomplicated influenza A and B in adolescents aged 12 years and older.

SHA:600566
Asia

Jumpcan Pharma Gains Protection Status for Traditional Chinese Medicine

Hubei Jumpcan Pharmaceutical (SHA:600566) said China's drug regulator granted Pudilan Xiaoyan oral liquid the status of nationally protected traditional Chinese medicine.The drug is used to treat upper respiratory infections, according to a Monday filing with the Shanghai bourse.The protection period is seven years from the announcement date.Shares of the pharmaceutical company were down 2% in recent trade.

SHA:600566
Asia

Jumpcan Pharma's Jianwei Xiaoshi Oral Liquid Added to China's Centralized Procurement Program

Hubei Jumpcan Pharmaceutical's (SHA:600566) Jianwei Xiaoshi Oral Liquid was selected for the National Chinese Patent Medicine's centralized procurement, according to a Friday disclosure to the Shanghai bourse.The drug is used to treat food stagnation and indigestion.During the procurement period, medical institutions will prioritize the use of the selected products, the pharmaceutical company said.

SHA:600566
Asia

Hubei Jumpcan Pharmaceutical's Attributable Profit Slides 9% in Q1

Hubei Jumpcan Pharmaceutical's (SHA:600566) attributable profit fell 9.1% to 400.1 million yuan in the first quarter from 440.3 million yuan in the year-ago period, according to a Friday filing with the Shanghai bourse.Earnings per share at the drug manufacturer decreased 8.3% to 0.44 yuan from 0.48 yuan in the prior-year period.Operating income declined 21% year over year to 1.21 billion yuan from 1.53 billion yuan.

SHA:600566
Asia

Jumpcan Pharma's 2025 Profit Drops 30%

Hubei Jumpcan Pharmaceutical's (SHA:600566) net profit attributable to shareholders in 2025 dropped 30% year on year to 1.78 billion yuan, or 1.93 yuan per share, according to a Shanghai bourse filing on Friday.Operating revenue fell 22% to 6.22 billion yuan from 8.02 billion yuan in the prior year.

SHA:600566

Track with the FINWIRES app suite

FolioX
FolioX
Track SHA:600566 in your portfolio
WheelAI
WheelAI
Analyze SHA:600566 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHA:600566